Questions over AstraZeneca’s COVID-19 vaccine data risk delaying approval

LONDON (Reuters) – Days after grabbing headlines with its COVID-19 “vaccine for the world”, AstraZeneca is facing tricky questions about its success rate that some experts say could hinder its chances of getting ...

Read more→